Intractable Brain Metastasis EGFR Mutant Lung Cancer Confirms Effectiveness Of 3rd Generation Tyrosine Kinase Inhibitors
Aug 20, 2024
The effect of a third-generation tyrosine kinase inhibitor 'lasertinib" in patients with brain metastatic EGFR mutant lung cancer who failed to be treated by conventional methods has been confirmed in clinical studies.
Professors Kim Hye-ryeon and Hong Min-hee of Yonsei Cancer Hospital said 55.3% of patients showed brain tumor reduction when laser tinib was used in patients with intractable brain metastasis EGFR mutant lung cancer along with Kang Jin-hyung of Seoul St. Mary's Hospital, Choi Yoon-ji of Korea University Anam Hospital, and Ahn Hee-kyung of Gachon University Gil Hospital.
The study, led by the Korean Society of Angiotherapy (KCSG), was published in the Journal of Oncology of the American Medical Association (JAMA Oncology, IF 28.4), which includes Yonsei Cancer Hospital, Seoul St. Mary's Hospital, Seoul National University Hospital, Seoul National University Hospital, Korea University Hospital, and Bundang Seoul National University Hospital.
EGFR gene mutations, which are easily found in non-small cell lung cancer, promote growth by activating the signaling pathway of tumor cells. The most important mediator of signal transduction in EGFR is tyrosine kinase.
Since lung cancer is an aggressive cancer that progresses quickly, 25% of patients have brain metastasis at the time of stage 4 diagnosis. This is why drugs to treat lung cancer patients with brain metastases are important. However, first and second generations of tyrosine kinase inhibitors were difficult to penetrate into the brain. This is due to the Blood Brain Barrier (BBB) that prevents drug delivery.
The research team confirmed the effect of lasertinib, a third-generation tyrosine kinase inhibitor, in patients with central nervous system metastatic lung cancer. The number of patients who participated in this clinical trial was 40 who failed treatment with first and second-generation drugs.
The objective response rate in the brain, which refers to the proportion of patients with reduced brain tumor size, was 55.3%. In particular, the effect was excellent with the T790M mutation, which manifests as first- and second-generation drug resistance. The objective response rate of mutant-positive patients reached 80% (42.9% of negative patients).
Progression-free survival, a period of survival without disease progression, was recorded as 15.8 months. There was no difference according to the T790M mutation. The periods of positive and negative patients were 15.2 months and 15.4 months, respectively.
In addition, the side effects of the patient remained at a minor level, confirming safety.
Professor Kim Hye-ryeon said "This study is significant in that it presented lasertinib, a third-generation EGFR inhibitor, as a new treatment strategy regardless of the occurrence of resistance mutation T790M in patients with EGFR-positive brain metastases who failed treatment"
Professors Kim Hye-ryeon and Hong Min-hee of Yonsei Cancer Hospital said 55.3% of patients showed brain tumor reduction when laser tinib was used in patients with intractable brain metastasis EGFR mutant lung cancer along with Kang Jin-hyung of Seoul St. Mary's Hospital, Choi Yoon-ji of Korea University Anam Hospital, and Ahn Hee-kyung of Gachon University Gil Hospital.
The study, led by the Korean Society of Angiotherapy (KCSG), was published in the Journal of Oncology of the American Medical Association (JAMA Oncology, IF 28.4), which includes Yonsei Cancer Hospital, Seoul St. Mary's Hospital, Seoul National University Hospital, Seoul National University Hospital, Korea University Hospital, and Bundang Seoul National University Hospital.
EGFR gene mutations, which are easily found in non-small cell lung cancer, promote growth by activating the signaling pathway of tumor cells. The most important mediator of signal transduction in EGFR is tyrosine kinase.
Since lung cancer is an aggressive cancer that progresses quickly, 25% of patients have brain metastasis at the time of stage 4 diagnosis. This is why drugs to treat lung cancer patients with brain metastases are important. However, first and second generations of tyrosine kinase inhibitors were difficult to penetrate into the brain. This is due to the Blood Brain Barrier (BBB) that prevents drug delivery.
The research team confirmed the effect of lasertinib, a third-generation tyrosine kinase inhibitor, in patients with central nervous system metastatic lung cancer. The number of patients who participated in this clinical trial was 40 who failed treatment with first and second-generation drugs.
The objective response rate in the brain, which refers to the proportion of patients with reduced brain tumor size, was 55.3%. In particular, the effect was excellent with the T790M mutation, which manifests as first- and second-generation drug resistance. The objective response rate of mutant-positive patients reached 80% (42.9% of negative patients).
Progression-free survival, a period of survival without disease progression, was recorded as 15.8 months. There was no difference according to the T790M mutation. The periods of positive and negative patients were 15.2 months and 15.4 months, respectively.
In addition, the side effects of the patient remained at a minor level, confirming safety.
Professor Kim Hye-ryeon said "This study is significant in that it presented lasertinib, a third-generation EGFR inhibitor, as a new treatment strategy regardless of the occurrence of resistance mutation T790M in patients with EGFR-positive brain metastases who failed treatment"
|
bellho@sportschosun.com
